The eighth annual Biotech Showcase™ investor and networking conference will be held in San Francisco during the healthcare industry’s busiest week of the year, January 11–13, 2016.
The event acts as home base for innovative mid-small cap and private life sciences companies and the public, private and strategic investors eager to meet with them. Over 300 innovative company presentations will take place during the three-day event.
“Biotech Showcase is a good opportunity not just to network and meet new people, but also to hear what young biotechs are doing, to gauge our peers’ interactions and to tell everyone about AstraZeneca’s recent deals and direction. It’s an opportunity to discuss challenges and where companies are heading, as well as the competitive landscape,” said Shaun Grady, VP, business development operations, AstraZeneca.
Monday’s lunch plenary, “The great pricing debate: Navigating through an industry sea change,” will address pricing issues that have the fragmented the biopharmaceutical industry. The plenary will be moderated by Mike Griffith – Executive VP Commercial Division, inVentiv Health, with panelists Ron Cohen – CEO, Acorda Therapeutics and Chairman, Biotechnology Industry Organization (BIO), and Beth L. Roberts – Partner, Hogan Lovells.
Tuesday’s lunch plenary, “State of the industry: It’s different this time,” will be moderated by Ben Bonifant – Founder and Partner, Triangle Insights Group, with panelists Philippe Lopes-Fernandes – Senior VP, Head, Global Licensing and Business Development, Merck KGaA, Darmstadt, Germany;
Diego Miralles – Head, Johnson & Johnson Innovation; and Dennis Purcell – Founder and Senior Advisor, Aisling Capital.
Wednesday’s lunch plenary is entitled “Bubble trouble? Have the biotech bulls had their run?” moderated by Eric W. Blanchard – Partner, Covington & Burling LLP, with panelists Asthika Goonewardene – Senior Biotechnology Analyst, Bloomberg Intelligence; Art Pappas – Managing Partner, Pappas Ventures; and Alex Zisson – Partner, Thomas McNerney & Partners.
In addition to the annual workshop “The Life Sciences Report 2016 small-cap watchlist,” on Tuesday, there will be a “Medtech Showcase State of the Industry Report” during Medtech Showcase on January 12 featuring panelists from ICON, AdvaMed, Cohera Medical, and MDIC. There will also be a Digital Health Showcase State of the Industry Report entitled “At the intersection of technology and medicine” during Digital Health Showcase on January 13 moderated by Yarmela Pavlovic – Partner, Hogan Lovells, and featuring panelists from GE Healthcare Life Care, PureTech and WellDoc.
Biotech Showcase is produced by Demy-Colton Life Science Advisors and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.
To register or for more information go to the Biotech Showcase 2016 website.
# # #
Follow Biotech Showcase 2016 on Twitter: @EBDGroup (hashtag: #BTS16).
Online Press Kit service for Biotech Showcase 2016 is available from PR Newswire to enhance your public relations efforts.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences include:
For more information please visit www.ebdgroup.com.
+1 760 930 0500
About Demy-Colton Life Science Advisors
Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life science industry. Demy-Colton has developed a number of high-value added conferences to address the business and development needs of the biotechnology industry; it provides partnering services and it has helped launch a unique investor website and newsletter.
Demy-Colton’s conferences include:
Demy-Colton’s online partnering system, Networking2™, supports Demy-Colton’s events and facilitates investor and venture meetings for the pharma industry and partnering for other organizations.
Andrew W. Mielach